A Targeted View  by unknown
Leading Edge
SelectA Targeted View
Crystal structures are invaluable assets in the rational design of targeted cancer therapeutics. In
this Select, we highlight a few recent structures of cancer-therapeutic targets cocrystallized with
novel or known inhibitors. These studies provide insights into the biological function of these pro-
teins, explain the molecular mechanisms of inhibitors, and pave the way for the rational design of
future targeted therapies.ThemTOR FRB domain (red) restricts access to the
kinase domain (pink) and has a dual substrate
recruitment/rapamycin-binding site (green). Image
courtesy of N. Pavletich.A Gatekeeper Guards the Path to mTOR
mTOR is a kinase that integrates nutrient and growth factor signals to coor-
dinate cellular growth control. Hyperactivation of mTOR has been implicated
in the growth of many cancer types for some time, but an informative crystal
structure of this crucial protein has remained elusive. For the first time, Yang
et al. solve the structure of a catalytically active portion of mTOR by cocrys-
tallization with a stabilizing obligatory complex member, mLst8. Cocrystalli-
zation with an ATP transition-state analog or an ATP-competitive inhibitor
provides mechanistic explanations for how this atypical kinase functions
and why inhibitors achieve specificity. One of the biggest surprises of the
structure is that it persists in an inherently active conformation. Rather
than affect enzymatic activity, regulatory mechanisms control substrate
recruitment and access to a deeply recessed active site. The active site is
guarded by, interestingly, the FKBP12-rapamycin (FRB)-binding domain of
mTOR, providing a potential mechanism of inhibition by the drug rapamycin.
In addition to sterically blocking nontargets from the active site, the FRB pro-
motes phosphorylation of genuine substrates by providing an auxiliaryrecruitment site. Cocrystallization with two ATP-competitive inhibitors, Torin2 and PP242, reveal that specificity over the
related phosphoinositide 3-kinases (PI3K) is conferred through extensive interactions with an mTOR-specific residue and
crucial conformational changes not possible in PI3Ks, respectively. Together, these structures and the insights that they pro-
vide should pave the way for development of potent, specific cancer therapeutics that target mTOR.
Yang, H., et al. (2013). Nature 497, 217–223.Structure of the human smoothened
receptor, critical in embryonic develop-
ment. Image generated by Katya Kady-
shevskaya, Stevens Laboratory, TSRI.A Controversy Smoothened Out
The smoothened (SMO) receptor is an essential component of the hedgehog (Hh)-
signaling pathway, which has been implicated in the development of certain types of
skin and brain tumors. SMO is a class F G-protein-coupled receptor (GPCR), but its
classification as a GPCR remains controversial because it has poor sequence conser-
vation (10% identity) to thepredominant classAGPCRs, and theHh-signalingpathway
lacks GPCR-like mechanisms. Wang et al. cocrystallize SMO with an antitumor SMO
antagonist, providing structural revelations about the conservation of SMO and con-
firming that the antagonist functions by binding a ligand cleft embedded in the distinc-
tive seven-transmembrane (7TM) bundle that is often considered synonymous with
GPCRs. Yet SMO also has many distinct features, including an extracellular domain
(ECD) linker and long extracellular loops (ECLs) that form intricate structures. The
ECLs are important for maintaining the receptor in an inactive state, and the disulfide
bonds thatmaintain theECD linker andECLstructuresarehighly conserved in theother
class F GPCRs, the Frizzled proteins, highlighting the functional importance of these
extracellular features. The extracellular orifice of the antagonist-binding ligand pocket
is created by the unique SMOECD linker and two extracellular loops, perhaps explain-
ing how the small molecule enters the center cavity. In summary, SMO has strong
structural conservation of the 7TM fold despite little sequence conservation with
canonical GPCRs and divergent downstream signaling. These data suggest that the
principles guiding the design of antagonists against other 7TMs might be applied to
the design of SMO inhibitors, and the solved structure of SMO provides a detailed
roadmap to facilitate developing better SMO antagonists to fight against cancers.
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X-ray structure of the potent and selec-
tive inhibitor WEHI-539 bound to the
canonical hydrophobic groove of BCL-
XL. Image courtesy of G. Lessene and
P. Czabotar.An XL Solution to Cell Death Resistance
BCL-XL is a member of the prosurvival BCL-2 family, which is endogenously antago-
nized through binding to the proapoptotic BH3-only proteins such as BIM. BCL-XL is
overexpressed in certain tumors and is strongly implicated as a chemoresistance fac-
tor; therefore, there has been considerable interest in the development of BH3 mi-
metics as a therapeutic strategy. However, the development of such drugs has
been difficult because of the need to target a large protein-protein interaction inter-
face and because achieving specificity has been challenging. Remarkably, Lessene
et al. use structure-guided medicinal chemistry to develop a novel, highly potent,
and selective inhibitor of BCL-XL that targets the protein-protein interface. They
initially screened a library of 100,000 compounds to identify a drug backbone that
can disrupt the BCL-XL—BIMBH3 interaction. Modeling was then used to guide
improvement of the drug through hypothesis-driven medicinal chemistry, but the
authors quickly turned to crystallization of drug candidates with BCL-XL to inform
further optimization strategies. Through multiple successive rounds of structure-guidedmedicinal chemistry, testing, and crystallization, the authors ultimately created an inhibitor with a7,000-fold increase
in affinity over the initial lead compound, which still retains a relatively low molecular weight, a common hurdle in developing
compounds that target protein-protein interactions. Furthermore, this compound has 400-fold higher affinity for BCL-XL over
other BCL-2 family members, making it the first inhibitor that is specific to BCL-XL. Finally, they show that their compound can
kill cells by selectively inhibiting BCL-XL, suggesting not only that it has therapeutic potential, but also that it may prove useful
in teasing out the unique cell-biological functions of BCL-XL.
Lessene, G., et al. (2013). Nat. Chem. Biol. Published online April 21, 2013. http://dx.doi.org/10.1038/nchembio.1246.Amolecule of AGI-6780 binds at the dimer interface
of mutant IDH2 (R140Q). Image courtesy of Eric D.
Smith.A Selective End to an Oncometabolite
Cancer-associated mutations in the active sites of isocitrate dehydrogenase
1 and 2 (IDH1 and IDH2) result in a gain-of-function enzymatic activity. Only
mutant IDH1/2 produce the oncometabolite (R)-2-hydroxyglutarate (2HG);
although the exact mechanism of oncogenesis by 2HG is unclear, current
data suggest that it functions by blocking cellular differentiation. Thus, inhi-
bition of mutant IDH1 or IDH2 is an attractive therapeutic target for cancers
with these mutations and would be useful for studying the mechanism of
2HG action. However, such an inhibitor would need to be selective for the
mutated isoform because the wild-type protein performs an essential func-
tion in the citric acid cycle. To generate such a specific compound, Wang
et al. initially screen a small-molecule library and then use X-ray crystallo-
graphic studies to refine and improve their drug. The authors create a com-
pound (AGI-6780) that functions allosterically yet is selective for the IDH2/
R140Q mutant over both wild-type IDH2 and mutated IDH1. Structural
studies reveal that AGI-6780 binds within the IDH2 dimer interface, coordi-
nated by a helix that is unfolded in the open IDH1 conformation, explaining
why AGI-6780 is specific to IDH2. Kinetic studies reveal that specificity for
the mutant IDH2 over wild-type IDH2 is achieved because the drug has
slow-tight binding. In a complementary study, the authors create an IDH1/
R132H inhibitor that is also specific for mutant IDH1 over wild-type IDH1
and mutant IDH2 (termed AGI-5198), although the binding interface was not structurally explored. Importantly, the authors
show that AGI-6780 and AGI-5198 induce differentiation of acute myeloid leukemia blasts and glioma cells derived from
patients with the IDH2/R140Q and IDH1/R132H mutations, respectively. In summary, these studies demonstrate that
targeted inhibition of mutant IDH enzymes is both feasible and a potentially viable therapeutic strategy for tumors with IDH
mutations.
Wang, F., et al. (2013). Science 340, 622–626.
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